Wall Street analysts predict that Regenxbio Inc (NASDAQ:RGNX) will report ($0.40) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Regenxbio’s earnings, with estimates ranging from ($1.19) to $0.25. Regenxbio reported earnings per share of $0.04 in the same quarter last year, which would indicate a negative year-over-year growth rate of 1,100%. The company is expected to report its next quarterly earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that Regenxbio will report full year earnings of ($2.15) per share for the current fiscal year, with EPS estimates ranging from ($3.06) to ($1.58). For the next financial year, analysts anticipate that the firm will post earnings of ($0.91) per share, with EPS estimates ranging from ($2.13) to $0.12. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Regenxbio.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.03). Regenxbio had a negative net margin of 99.57% and a negative return on equity of 18.74%. The company had revenue of $14.70 million during the quarter, compared to analysts’ expectations of $7.46 million. During the same quarter in the prior year, the business posted ($0.56) earnings per share. The company’s revenue was up 177.0% compared to the same quarter last year.
RGNX has been the subject of several analyst reports. Leerink Swann raised Regenxbio from an “underperform” rating to a “market perform” rating in a report on Tuesday, August 20th. They noted that the move was a valuation call. Chardan Capital set a $150.00 price objective on Regenxbio and gave the company a “buy” rating in a report on Wednesday, September 4th. Evercore ISI reissued a “buy” rating and issued a $65.00 price objective on shares of Regenxbio in a report on Monday, November 11th. Svb Leerink raised Regenxbio from an “underperform” rating to a “market perform” rating and decreased their price objective for the company from $38.00 to $37.00 in a report on Tuesday, August 20th. Finally, ValuEngine raised Regenxbio from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $72.38.
In related news, insider Kenneth T. Mills sold 15,000 shares of Regenxbio stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $37.55, for a total value of $563,250.00. Following the completion of the transaction, the insider now owns 261,000 shares in the company, valued at approximately $9,800,550. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kenneth T. Mills sold 10,000 shares of Regenxbio stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $39.75, for a total value of $397,500.00. Following the completion of the transaction, the chief executive officer now owns 251,000 shares of the company’s stock, valued at approximately $9,977,250. The disclosure for this sale can be found here. In the last three months, insiders sold 30,486 shares of company stock valued at $1,191,162. Insiders own 13.80% of the company’s stock.
Several institutional investors have recently made changes to their positions in RGNX. Oregon Public Employees Retirement Fund increased its stake in shares of Regenxbio by 4.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 12,158 shares of the biotechnology company’s stock valued at $625,000 after purchasing an additional 498 shares in the last quarter. NEXT Financial Group Inc purchased a new position in shares of Regenxbio in the 2nd quarter valued at about $69,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in shares of Regenxbio in the 2nd quarter valued at about $290,000. Fox Run Management L.L.C. purchased a new position in shares of Regenxbio in the 2nd quarter valued at about $269,000. Finally, Arizona State Retirement System increased its stake in shares of Regenxbio by 1.2% in the 2nd quarter. Arizona State Retirement System now owns 47,739 shares of the biotechnology company’s stock valued at $2,452,000 after purchasing an additional 547 shares in the last quarter. Hedge funds and other institutional investors own 79.54% of the company’s stock.
Shares of NASDAQ:RGNX traded up $0.84 on Thursday, reaching $37.16. The company had a trading volume of 338,800 shares, compared to its average volume of 520,550. The firm has a market capitalization of $1.34 billion, a PE ratio of 15.61 and a beta of 0.81. The firm’s 50 day simple moving average is $37.59 and its 200-day simple moving average is $42.32. The company has a current ratio of 11.49, a quick ratio of 11.49 and a debt-to-equity ratio of 0.01. Regenxbio has a 52-week low of $30.38 and a 52-week high of $65.62.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Featured Story: Understanding Market Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.